Drug intelligence / Profile preview

WT-X18

Development stage: Preclinical
Lead developer: Hangzhou Westan Pharmaceutical Technology
Modality: Small Molecules

Overview

WT-X18 is a small molecule drug candidate currently under development by Hangzhou Westan Pharmaceutical Technology. It is positioned within the company's pipeline for the treatment of respiratory diseases. As of the current development stage, the compound is in the preclinical phase, specifically focused on target selection and validation. Detailed information regarding its specific biological target, mechanism of action, and pharmacological profile has not yet been publicly disclosed by the developer.

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on WT-X18.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WT-X18.

Explore the full profile